Fresenius SE SG&A Expenses 2016-2024 | FSNUY

Fresenius SE annual/quarterly sg&a expenses history and growth rate from 2016 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
  • Fresenius SE sg&a expenses for the quarter ending June 30, 2024 were $0.866B, a 50.03% decline year-over-year.
  • Fresenius SE sg&a expenses for the twelve months ending June 30, 2024 were $1.679B, a 76.3% decline year-over-year.
  • Fresenius SE annual sg&a expenses for 2023 were $3.415B, a 51.94% decline from 2022.
  • Fresenius SE annual sg&a expenses for 2022 were $7.105B, a 10.14% increase from 2021.
  • Fresenius SE annual sg&a expenses for 2021 were $6.451B, a 4.01% increase from 2020.
Fresenius SE Annual SG&A Expenses
(Millions of US $)
2023 $3,415
2022 $7,105
2021 $6,451
2020 $6,203
2019 $6,055
2018 $5,755
2017 $6,261
2016 $4,759
2015 $4,658
Fresenius SE Quarterly SG&A Expenses
(Millions of US $)
2024-06-30 $866
2024-03-31 $769
2023-12-31 $-779
2023-09-30 $823
2023-06-30 $1,733
2023-03-31 $1,638
2022-12-31 $2,092
2022-09-30 $1,621
2022-06-30 $1,736
2022-03-31 $1,657
2021-12-31 $1,705
2021-09-30 $1,533
2021-06-30 $1,687
2021-03-31 $1,526
2020-12-31 $1,866
2020-09-30 $1,437
2020-06-30 $1,360
2020-03-31 $1,540
2019-12-31 $1,796
2019-09-30 $1,378
2019-06-30 $1,477
2019-03-31 $1,404
2018-12-31 $1,512
2018-09-30 $1,400
2018-06-30 $1,438
2018-03-31 $1,405
2017-12-31 $1,865
2017-09-30 $1,463
2017-06-30 $1,487
2017-03-31 $1,445
2016-12-31 $1,196
2016-09-30 $1,215
2016-06-30 $1,169
2016-03-31 $1,179
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $19.704B $24.011B
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
Stock Name Country Market Cap PE Ratio
Quest Diagnostics (DGX) United States $16.912B 17.14
DaVita (DVA) United States $12.098B 15.65
Encompass Health (EHC) United States $9.453B 22.29
Chemed (CHE) United States $7.853B 24.14
Elanco Animal Health (ELAN) United States $5.843B 13.91
RadNet (RDNT) United States $5.284B 117.02
Option Care Health (OPCH) United States $3.848B 18.23
Amedisys (AMED) United States $2.744B 19.53
LifeStance Health (LFST) United States $2.698B 0.00
Addus HomeCare (ADUS) United States $2.350B 27.57
Astrana Health (ASTH) United States $1.974B 26.99
U.S Physical Therapy (USPH) United States $1.380B 36.27
Pennant (PNTG) United States $0.938B 37.92
Aveanna Healthcare Holdings (AVAH) United States $0.873B 0.00
Atai Life Sciences (ATAI) Germany $0.200B 0.00
Bioqual (BIOQ) United States $0.059B 0.00
Daxor (DXR) United States $0.039B 0.00
Ontrak (OTRK) United States $0.006B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.005B 0.00
IMAC Holdings (BACK) United States $0.001B 0.00
Psychemedics (PMD) United States $0.000B 0.00